ISRCTN68985072 https://doi.org/10.1186/ISRCTN68985072

Efficiency of Proton pump Inhibitors in Patients with gastro-oesophageal reflux symptoms

Submission date 24/10/2006	**Recruitment status** No longer recruiting	[ ] Prospectively registered [ ] Protocol [ ] Statistical analysis plan [ ] Results [ ] Individual participant data [ ] Record updated in last year
Registration date 24/04/2007	**Overall study status** Completed	
Last Edited 22/09/2021	**Condition category** Digestive System	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr P J F de Jonge

Contact details
's-Gravendijkwal 230
Rotterdam
Netherlands
3015 CE
+31 (0)10 463 5528
p.dejonge@erasmusmc.nl

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
N/A

Study information

Scientific Title
Efficiency of Proton pump Inhibitors in Patients with gastro-oesophageal reflux symptoms

Acronym
PIP study

Study objectives
1. To determine subgroups of patients with gastro-oesophageal reflux symptoms according to endoscopy and pH monitoring
2. To evaluate the differences in the subgroups of patients with Gastro-oEsophageal Reflux Disease (GERD) symptoms in:
a. duration of Proton Pump Inhibitor (PPI) treatment (four versus eight weeks)
b. inflammatory reaction
c. prevalence of Helicobacter pylori
d. occurrence of symptoms
3. To evaluate treatment of GERD patients with PPIs for four or eight weeks in order to determine the effectiveness of the PPI treatment
4. To evaluate the effect of PPI treatment on:
a. symptom relief
b. inflammatory reaction in the oesophagus

Ethics approval required
Old ethics approval format

Ethics approval(s)
Approval received from the Medical Ethics Committee (Medisch Ethische Toetsings Commissie Erasmus MC) (ref: MEC-2005-141).

Study design
Randomised multicentre trial

Primary study design
Interventional

Secondary study design
Multi-centre

Study setting(s)
Hospital

Study type(s)
Treatment

Participant information sheet

Health condition(s) or problem(s) studied
Gastro-oesophageal reflux disease

Interventions
All patients will undergo a baseline endoscopy and follow up endoscopy with biopsies, then they all will undergo a wireless oesophageal 48 hour pH monitoring study, and finally these patients

will be randomised to either four weeks or eight weeks of 20 mg once daily rabeprazole treatment.

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
Rabeprazole

Primary outcome measure
Differences in the subgroups of patients with GERD symptoms in:
1. Duration of PPI treatment (four versus eight weeks)
2. Inflammatory reaction
3. Prevalence of H. pylori
4. Occurrence of symptoms

Secondary outcome measures
Effect of PPI treatment on:
1. Symptom relief
2. Inflammatory reaction in the oesophagus

Overall study start date
01/10/2005

Completion date
01/10/2008

Eligibility

Key inclusion criteria
1. Aged 18 years or older
2. Symptoms of GERD as determined by the GERD-Health Related Quality of Life (HRQL) questionnaire (score more than or equal to 12)
3. Informed consent

Participant type(s)
Patient

Age group
Adult

Lower age limit
18 Years

Sex
Not Specified

Target number of participants
415

Key exclusion criteria
1. Aged under 18 years
2. Unable to fill out questionnaire
3. Previous history of upper Gastro-Intestinal (GI) tract cancer
4. Previous history of achalasia
5. Previous surgery to the oesophagus or stomach
6. Endoscopically demonstrated and histologically proven complicated reflux disease (ulcer, stricture, Barretts esophagus)
7. Coagulation disorder if uncorrected at the time of endoscopy
8. Use of warfarin or other anti-coagulant medication if uncorrected at the time of endoscopy
9. Liver cirrhosis
10. Pregnancy and lactation
11. Contraindications to the study medication

Date of first enrolment
01/10/2005

Date of final enrolment
01/10/2008

Locations

Countries of recruitment
Netherlands

Study participating centre
's-Gravendijkwal 230
Rotterdam
Netherlands
3015 CE

Sponsor information

Organisation
Erasmus Medical Center (The Netherlands)

Sponsor details
University Medical Center Rotterdam
s-Gravendijkwal 230
Rotterdam
Netherlands
3015 CE

+31 (0)10 463 55 28
p.dejonge@erasmusmc.nl

Sponsor type
Hospital/treatment centre

Website
http://www.erasmusmc.nl/content/englishindex.htm

ROR
https://ror.org/018906e22

Funder(s)

Funder type
Industry

Funder Name
Janssen & Cilag B.V. (The Netherlands)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration